Company: DHR
Filing Date: 2025-07-22
Form Type: 10-Q
Source: 0000313616-25-000153
Chunk: 112

Company: DANAHER CORP /DE/
Filing Date: 2025-07-22
Form: 10-Q
Item: Item 8
Chunk 112
---
309 $2,260 $4,758 $4,787 Operating profit554 556 1,272 1,386 Depreciation100 100 200 197 Amortization of intangible assets48 48 96 96 Operating profit as a % of sales24.0 %24.6 %26.7 %29.0 %Depreciation as a % of sales4.3 %4.4 %4.2 %4.1 %Amortization as a % of sales2.1 %2.1 %2.0 %2.0 %

Sales Growth (Decline) and Core Sales Growth

% Change Three-Month Period Ended June 27, 2025 vs. Comparable 2024 Period% Change Six-Month Period Ended June 27, 2025 vs. Comparable 2024 PeriodTotal sales growth (decline) (GAAP)2.0 %(0.5)%Impact of:Divestitures0.5 %0.5 %Currency exchange rates (0.5)%— %Core sales growth (non-GAAP)2.0 %— %

Price decreases in the segment of 1.0%, attributable to factors discussed below, negatively impacted the year-over-year change in sales during both the three and six-month periods ended June 27, 2025 and are reflected as a component of core sales above.

Total segment sales increased 2.0% during the three-month period primarily as a result of increased core sales and to a lesser extent currency exchange rates, net of the impact of divestitures.  Total segment sales decreased 0.5% during the six-month period as a result of the impact of divestitures.  In the three-month period, the increase in segment core sales was primarily driven by increased year-over-year demand for consumables, partially offset by decreased demand for equipment.  In the six-month period, core sales were flat as increased year-over-year demand for consumables was offset by lower demand for equipment.  Geographically, increased core sales in North America and most other major markets were offset by decreased core sales in China attributable to the pricing impact of China’s volume-based procurement program and healthcare reimbursement changes in both periods.  

31

During the three-month period, core sales growth in the molecular diagnostics business increased year-over-year as core sales in non-respiratory tests more than